1 Kwon-Chung K J, Bentett J E. Epidemiologic differences between the two varieties of Cryptococcus neoformans [J]. American journal of epidemiology, 1984, 120(1): 123-30.
2 Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group [J]. Clinical infectious diseases, 2000, 31(2): 499-508.
3 Harris J, Lockhart S, Chiller T. Cryptococcus gattii: where do we go from here? [J]. Medical mycology, 2012, 50(2): 113-29.
4 Kidd S E, Hagen F, Tscharke R L, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) [J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(49): 17258-63.
5 Byrnes E J, 3RD, Li W, Lewit Y, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States [J]. PLoS pathogens, 2010, 6(4): e1000850.
6 Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China [J]. Fungal Genet Biol, 2015, 78(7-15.
7 Kwon-Chung K J, Polacheck I, Bennett J E. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C) [J]. Journal of clinical microbiology, 1982, 15(3): 535-7.
8 Meyer W, Aanensen D M, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii [J]. Medical mycology, 2009, 47(6): 561-70.
9 Fraser J A, Giles S S, Wenink E C, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak [J]. Nature, 2005, 437(7063): 1360-4.
10 Klein K R, Hall L, Deml S M, et al. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing [J]. Journal of clinical microbiology, 2009, 47(11): 3669-72.
11 Chen J, Varma A, Diaz M R, et al. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China [J]. Emerging infectious diseases, 2008, 14(5): 755-62.
12 Feng X, Yao Z, Ren D, et al. Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients [J]. FEMS Yeast Res, 2008, 8(6): 930-8.
13 Xue X, Wu H, Wang K, et al. Cryptococcosis by Cryptococcus gattii in China [J]. The Lancet Infectious Diseases, 2015, 15(10): 1135-6.
14 Lockhart S R, Iqbal N, Harris J R, et al. Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates [J]. PloS one, 2013, 8(9): e74737.
15 Datta K, Bartlett K H, BAER R, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States [J]. Emerging infectious diseases, 2009, 15(8): 1185-91.
16 Chen Y C, Chang S C, Shih C C, et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan [J]. Diagnostic microbiology and infectious disease, 2000, 36(3): 175-83.
17 Torres-Rodriguez J M, Alvarado-Ramirez E, Murciano F, et al. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii [J]. The Journal of antimicrobial chemotherapy, 2008, 62(1): 205-6.
18 Hagen F, Ilnait-Zaragozi M T, Bartlett K H, et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates [J]. Antimicrob Agents Chemother, 2010, 54(12): 5139-45.
19 Espinel-Ingroff A, Aller A I, Canton E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole [J]. Antimicrob Agents Chemother, 2012, 56(11): 5898-906.
20 Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine [J]. Antimicrob Agents Chemother, 2012, 56(6): 3107-13.
21 Lockhart S R, Iqbal N, Bolden C B, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility [J]. Diagnostic microbiology and infectious disease, 2012, 73(2): 144-8.
22 Bielsk A E, May R C. What makes Cryptococcus gattii a pathogen? [J]. FEMS Yeast Res, 2016, 16(1): fov106.
23 Ngamskulrungroj P, Chang Y, Sionov E, et al. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model [J]. mBio, 2012, 3(3):
24 ChenS C, Meyer W, Sorrell T C. Cryptococcus gattii infections [J]. Clin Microbiol Rev, 2014, 27(4): 980-1024.
25 Ngamskulrungroj P, Serena C, Gilgado F, et al. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype [J]. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, 17(2): 251-8.